Bausch + Lomb Q1 revenue $1.099B (+18% YoY); raises FY constant-currency growth guidance

Bausch & Lomb Corp

2024-Q1 EPS reported -$0.48 revenue$1,099,000,000

GAAP net loss attributable widened to $167M from $90M; adjusted EBITDA rose to $180M from $141M.
Vision Care revenue $635M (+8% reported, +11% constant currency); Surgical $197M (+8%); Pharmaceuticals $267M (+66% on XIIDRA/MIEBO).
Raises FY constant-currency revenue growth guidance to 13-15% from 12-14%; revenue range now $4.600-$4.700B.
Adjusted EPS (non-GAAP) $0.07 vs $0.10; GAAP EPS ($0.48) vs ($0.26).
Cash from operations $41M vs use of $56M in Q1 2023; foreign-exchange headwind estimated at $90M for FY.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Bausch & Lomb Corp reported the quarter ended March 31, 2024 results: revenue $1.099 billion, net income $167 million, EPS ($0.48). Guidance raised.

Period: the quarter ended March 31, 2024
Revenue: $1.099 billion
Net income: $167 million
EPS: ($0.48)
Guidance: raised
Result: reported results

Exact text from the filing

statement or other document pursuant to the Securities Act of 1933, as amended. --- EX-99.1 (EX-99.1) --- Bausch + Lomb Announces First-Quarter 2024 Results • Revenue of $1.099 Billion • GAAP Net Loss Attributable to Bausch + Lomb Corporation of $167 Million • Adjusted EBITDA (non-GAAP) 1 of $180 Million • Revenue Grew 18% as Reported and 20% on a Constant

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Bausch & Lomb Corp filing history →

Source: SEC EDGAR

accession 0001860742-24-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.